Growth Metrics

Eli Lilly (LLY) Other Working Capital Changes (2016 - 2026)

Eli Lilly filings provide 18 years of Other Working Capital Changes readings, the most recent being -$175.0 million for Q1 2026.

  • On a quarterly basis, Other Working Capital Changes fell 136.92% to -$175.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.0 billion, a 69.97% increase, with the full-year FY2025 number at $6.6 billion, up 98.41% from a year prior.
  • Other Working Capital Changes hit -$175.0 million in Q1 2026 for Eli Lilly, down from $5.9 billion in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.9 billion in Q4 2025 to a low of -$4.9 billion in Q3 2025.
  • Median Other Working Capital Changes over the past 5 years was $298.6 million (2024), compared with a mean of $639.9 million.
  • Biggest five-year swings in Other Working Capital Changes: crashed 319.57% in 2023 and later skyrocketed 16253.92% in 2025.
  • Eli Lilly's Other Working Capital Changes stood at $481.4 million in 2022, then decreased by 9.39% to $436.2 million in 2023, then tumbled by 60.82% to $170.9 million in 2024, then surged by 3368.4% to $5.9 billion in 2025, then crashed by 102.95% to -$175.0 million in 2026.
  • The last three reported values for Other Working Capital Changes were -$175.0 million (Q1 2026), $5.9 billion (Q4 2025), and -$4.9 billion (Q3 2025) per Business Quant data.